Almotriptan

BRAND NAMES

Axert (widely known, especially in the US and some other countries)

MECHANISM OF ACTION

Almotriptan works by targeting the underlying processes involved in a Migraine attack, mainly through its action on serotonin receptors.

PHARMACOKINETICS

Absorption

• Rapid oral absorption: Almotriptan is well absorbed after oral administration. 

• High bioavailability: Approximately 70–80%, which is relatively high compared to some other triptans. 

• Time to peak concentration (Tmax): About 1.5–3 hours after ingestion. 

• Food effect: Food has minimal or no significant effect on its absorption. 

• Onset of action: Clinical relief usually begins within 1–2 hours.

Distribution

• Moderate protein binding: About 35–40% of almotriptan binds to plasma proteins.  Wide tissue distribution: It distributes effectively throughout body tissues. 

• Crosses the blood–brain barrier: Allows it to act centrally on migraine pathways in the brain. 

• Volume of distribution (Vd): Approximately 180–200 L, indicating extensive distribution beyond the bloodstream.

Metabolism

Almotriptan is primarily metabolized in the liver through multiple pathways, including Monoamine oxidase A and cytochrome P450 enzymes such as CYP3A4 and CYP2D6.

Elimination

• Almotriptan is eliminated primarily through renal excretion, with about half of the dose excreted unchanged in the urine and the rest as inactive metabolites.

• Its elimination half-life is approximately 3–4 hours, allowing relatively rapid clearance from the body.

PHARMACODYNAMICS

Almotriptan is a selective agonist of 5-HT1B receptor and 5-HT1D receptor, which are involved in the regulation of cranial blood vessel tone and neurotransmitter release. It works by causing constriction of dilated blood vessels in the brain that are associated with migraine attacks.

In addition, it inhibits the release of pro-inflammatory neuropeptides from trigeminal nerve endings, thereby reducing neurogenic inflammation in the meninges. Through these combined actions, almotriptan effectively relieves migraine symptoms by blocking the transmission of pain signals in the trigeminal pathway.

ADMINISTRATION

1. Oral (tablet form) 

2. Taken with or without food

3. Should be taken at the first sign of a Migraine attack 

4.   Can still be effective if taken later, but early use gives better results.

DOSAGE AND STRENGTH

1. 6.25 mg tablets 

2. 12.5 mg tablets

3. Initial dose: 6.25 mg or 12.5 mg (taken orally) 

4. If migraine persists or returns

DRUG INTERACTIONS

Almotriptan can interact with several drugs, mainly due to its serotonergic activity and metabolism.

1. Examples: ergotamine, dihydroergotamine 

2. Effect: Risk of prolonged vasospasm (severe vasoconstriction) 

3. Recommendation: Avoid use within 24 hours of each other.

FOOD INTERACTIONS

1. Food has minimal to no clinically significant effect on the absorption of almotriptan. 

2. It can be taken with or without food. 

3. Bioavailability remains largely unchanged even when taken after meals.

CONTRAINDICATIONS

Almotriptan should not be used in the following conditions:

1. Angina pectoris 

2. History of myocardial infarction 

3. Coronary artery disease

SIDE EFFECTS

Side effects are generally mild to moderate and usually transient.

1. Dizziness 

2. Drowsiness (somnolence) 

3. Fatigue 

4. Nausea 

5. Dry mouth 

6. Headache (sometimes) 

7. Sensations of tingling or numbness (paresthesia) 

TOXICITY

Almotriptan is generally well tolerated at therapeutic doses, but toxicity may occur with overdose or in sensitive individuals. Common adverse effects include dizziness, drowsiness, nausea, and dry mouth, while more serious effects can involve chest tightness or increased blood pressure due to vasoconstriction.

In rare cases, excessive use may lead to Serotonin syndrome, especially when combined with other serotonergic drugs. Severe toxicity can also increase the risk of cardiovascular complications, particularly in patients with underlying heart disease.